Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sat · 31 Oct 2026
Standard addition

Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.

Oral orforglipron produced substantially more weight loss than placebo over 72 weeks in Japanese participants, offering a potential new medication option for obesity.

This double-blind randomized placebo-controlled phase 3 trial examined efficacy and safety of oral orforglipron for obesity. At 72 weeks, each orforglipron dose produced substantially more clinically meaningful weight loss than placebo in the randomized trial.

What the study was

Study design
Double-blind randomized placebo-controlled phase 3 trial
Population
238 Japanese adults with obesity disease
Sample size
238
Category
Treatment Innovation
Maturity
Validated
Journal
The lancet. Diabetes & endocrinology

Why it surfaced

Retained as a high-priority double-blind randomized placebo-controlled phase 3 trial after PubMed abstract review; the score reflects clinical relevance, design strength, novelty, and population need under the v1.3 conservative rubric.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.